2026 Speakers
Valdas Jurkauskas, Ph.D., Senior Vice President, Oxia Therapeutics
The Three Cs of CDMO Selection: Capability, Capacity and Cost
Eric Langer, President and Managing Partner, BioPlan Associates, Inc.
The Biomanufacturing Capacity Crunch: Where CDMO Demand Is Still Outrunning Supply
Director, Regulatory Affairs, Amneal Pharmaceuticals
Before FDA Pushback: Using Regulatory Intelligence to De-Risk CMC Submissions
Michael Spangler, Principal Consultant, Spangler Consulting
Check Before You Choose: Making CDMO References Calls
Principal Consultant, Tunnell Consulting
Beyond the Contract: Turning Partnerships into Performance
